New myocardial infarction definition affects incidence, mortality, hospitalization rates and prognosis

Abstract

Aims: To analyse differences in myocardial infarction incidence, mortality and hospitalization rates, 28-day case-fatality and two-year prognosis using two myocardial infarction case definitions: the classical World Health Organization definition (1994) and the European Society of Cardiology/American College of Cardiology definition (2000), which added cardiac troponin as a diagnostic biomarker. Design: Population-based cohort of 4170 consecutive myocardial infarction patients aged 35-74 years from Girona (Spain) recruited between 2002 and 2009. Methods: Incidence, mortality rates standardized to the European population and 28-day case-fatality were calculated. To estimate the association between case definition and prognosis, Cox models were fitted. Results: Use of the 2000 European Society of Cardiology/American College of Cardiology definition significantly increased myocardial infarction incidence per 100,000 population (238.3 vs. 274.5 in men and 54.1 vs. 69.7 in women). Applying this definition decreased the 28-day case-fatality rate from 26.9% to 23.4% in men, and from 31.0% to 24.1% in women. In the acute phase, patients diagnosed only by increased troponins were significantly less treated with thrombolysis (34.4% vs. 2.0%), angiotensin-converting enzyme inhibitors (71.7% vs. 65.0%) and percutaneous coronary intervention (41.1% vs. 31.7%). Case-fatality at 28 days was significantly better in cases diagnosed only by troponin increase (0.2 % vs. 9.7%), but two-year cardiovascular mortality was higher (7.5% vs. 3.7%). Conclusions: Inclusion of cardiac troponins in myocardial infarction diagnosis increased annual incidence and decreased case-fatality. Diagnosis based only on increased troponins was associated with worse outcome. This group of patients at high risk of death should receive aggressive secondary prevention therapy.

FSTL1 as a Potential Mediator of Exercise-Induced Cardioprotection in Post-Myocardial Infarction Rats

“…Myocardial infarction (MI) is a leading cause of mortality and morbidity in the world123. Pathologically, MI results in immediate tissue damage due to myocardial ischemia, followed by biochemical changes triggered by reperfusion and pathological remodeling, leading to left ventricular (LV) heart failure and mortality45.…”

Adropin as a potential marker of enzyme-positive acute coronary syndrome

“…The World Health Organisation predicts that by 2020, 37% of all deaths worldwide will be from CVDs 22. Health innovations are widely used, but ACS, a lethal manifestation of CVD, remains the leading cause of death worldwide 28. Currently, cardiac biomarkers (especially cTI and cTnT) are the most important diagnostic laboratory tests for ACS.8 Each year worldwide a million patients with suspected ACS are admitted to emergency, cardiology and cardiovascular surgery departments but only around 10% of cases are then confirmed 9.…”

Prevalence and Prognosis of High-risk Myocardial Infarction Patient Candidates to Extended Antiplatelet Therapy

“…IBERICA Registry estimates, adjusted for clustering and for the 2000 AMI definition change, 11 were used for the population aged 45-74 years, under the assumption that AMI incidence did not change substantially in the last 17 years. 12 The REGICOR Registry was used to estimate AMI incidence in the population > 74 years, which was weighted for the expected difference between incidence rates from Girona and Spain observed in the IBERICA Study ( Prevalence of PEGASUS characteristics in stable AMI patients ≥ 50 years old (Tables 3 and 4 of the supplementary material) was obtained using REGICOR AMI patient admission data, excluding patients who died or had a subsequent AMI during the first year after the index AMI.…”